Building the U.S. peptide platform.
VitaNova is the firm's life-sciences vehicle, capitalizing a $250 million peptide manufacturing and compounding platform. We are assembling qualified manufacturing, licensed U.S. compounding, and selected GMP real estate — only where we own the operating tenant — into one exit-ready enterprise.
The critical middle of the peptide value chain.
- VitaNova LLC
- The operating company.
- VitaNova Capital
- The investment vehicle, formed under Northcap Strategic Advisors.
VitaNova is a sponsor-led platform created to own the critical middle of the peptide value chain in the United States: qualified manufacturing, licensed compounding at scale, and the facilities that house them.
The work is underway. Capital, manufacturing, and compounding are being lined into a single operating structure — not a loose set of partnerships.
The manufacturer is not named while the transaction is in formation.
The manufacturer in focus is a specialized peptide API and injectable producer with FDA on-site inspection history, GLP-1 compounds already in the U.S. filing system, and commercial-scale lines for both drug substance and finished sterile product.
VitaNova is aligning that capability with a U.S. compounding and platform strategy under a $250 million capitalization.
Three pieces, held under one structure.
- 01
Peptide API & CDMO
High-potency peptide manufacturing, with a bias toward GLP-1 and adjacent molecules that already have commercial pull. The objective is controlled supply, not brokerage.
- 02
503A / 503B compounding
Licensed U.S. compounding capacity that takes qualified API into finished, compliant product. This is where margin and customer control sit.
- 03
GMP real estate, only with the tenant
We do not buy empty lab buildings. Real estate is acquired when it is attached to an operating manufacturing or compounding tenant we own or will own.
Demand moved. Capacity did not.
Peptide demand has moved from specialty to mass-market. Manufacturing and licensed compounding have not. That gap is producing strained supply and a set of subscale operators that cannot get to institutional quality on their own.
VitaNova is built for that gap — a single platform that can source, make, compound, and house peptide products under one quality and capital structure, then be sold as a whole.
Status
Platform in active formation. Capital raise open to qualified investors.
VitaNova Capital is raising to capitalize a $250 million peptide manufacturing and compounding platform.
Capital is used to secure manufacturing, stand up U.S. compounding, fund quality systems and working inventory, and hold the assets inside one vehicle. The sponsor’s mandate is platform construction and investor relations.
Materials are available to qualified investors on request.
VitaNova is a platform of Northcap Strategic Advisors. Information on this site is for discussion with qualified investors only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security. Offers are made only pursuant to definitive offering documents and applicable exemptions under U.S. securities law.
Legal & disclosures